Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial

医学 2型糖尿病 肾脏疾病 糖尿病 临床终点 内科学 随机对照试验 重症监护医学 内分泌学
作者
Hiddo J.L. Heerspink,Andreas L. Birkenfeld,David Z.I. Cherney,Helen M. Colhoun,Linong Ji,Chantal Mathieu,Per‐Henrik Groop,Richard E. Pratley,Sylvia E. Rosas,Peter Rossing,Jay S. Skyler,Katherine R. Tuttle,Robert Lawatscheck,Charlie Scott,Robert Edfors,Markus F. Scheerer,Peter Kolkhof,Janet B. McGill
出处
期刊:Diabetes Research and Clinical Practice [Elsevier]
卷期号:204: 110908-110908 被引量:9
标识
DOI:10.1016/j.diabres.2023.110908
摘要

Despite guideline-recommended treatments, including renin angiotensin system inhibition, up to 40 % of individuals with type 1 diabetes develop chronic kidney disease (CKD) putting them at risk of kidney failure. Finerenone is approved to reduce the risk of kidney failure in individuals with type 2 diabetes. We postulate that finerenone will demonstrate benefits on kidney outcomes in people with type 1 diabetes.FINE-ONE (NCT05901831) is a randomised, placebo-controlled, double-blind phase III trial of 7.5 months' duration in ∼220 adults with type 1 diabetes, urine albumin/creatinine ratio (UACR) of ≥ 200-< 5000 mg/g (≥ 22.6-< 565 mg/mmol) and eGFR of ≥ 25-< 90 ml/min/1.73 m2.The primary endpoint is relative change in UACR from baseline over 6 months. UACR is used as a bridging biomarker (BB), since the treatment effect of finerenone on UACR was associated with its efficacy on kidney outcomes in the type 2 diabetes trials. Based on regulatory authority feedback, UACR can be used as a BB for kidney outcomes to support registration of finerenone in type 1 diabetes, provided necessary criteria are met. Secondary outcomes include incidences of treatment-emergent adverse events, treatment-emergent serious adverse events and hyperkalaemia.FINE-ONE will evaluate the efficacy and safety of finerenone in type 1 diabetes and CKD. Finerenone could become the first registered treatment for CKD associated with type 1 diabetes in almost 30 years.ClinicalTrials.gov NCT05901831.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
shylockcai发布了新的文献求助10
2秒前
lyl完成签到,获得积分10
2秒前
Jocd完成签到,获得积分10
2秒前
Akim应助孙二二采纳,获得10
3秒前
优雅的千凝完成签到,获得积分10
3秒前
Time完成签到,获得积分10
4秒前
格拉希尔完成签到 ,获得积分10
5秒前
Yzh完成签到,获得积分10
6秒前
shuke完成签到,获得积分10
7秒前
啊七飞完成签到,获得积分10
7秒前
琦琦国王完成签到,获得积分10
8秒前
务实的绝悟完成签到,获得积分10
11秒前
经纲完成签到 ,获得积分0
11秒前
我说苏卡你说不列完成签到,获得积分10
13秒前
CipherSage应助科研通管家采纳,获得10
15秒前
15秒前
顾矜应助科研通管家采纳,获得10
15秒前
15秒前
劲秉应助科研通管家采纳,获得10
15秒前
sun应助科研通管家采纳,获得20
15秒前
苗条绝义应助科研通管家采纳,获得10
16秒前
隐形曼青应助科研通管家采纳,获得10
16秒前
科研通AI5应助科研通管家采纳,获得10
16秒前
蔡从安完成签到,获得积分20
16秒前
劲秉应助科研通管家采纳,获得10
16秒前
CipherSage应助科研通管家采纳,获得10
16秒前
NexusExplorer应助科研通管家采纳,获得10
16秒前
黑囡应助科研通管家采纳,获得10
16秒前
16秒前
科研通AI5应助科研通管家采纳,获得10
16秒前
科研通AI2S应助科研通管家采纳,获得10
16秒前
5165asd完成签到 ,获得积分10
17秒前
ritata完成签到 ,获得积分10
18秒前
小彤完成签到 ,获得积分10
19秒前
19秒前
ll应助蔡从安采纳,获得10
20秒前
boltos完成签到,获得积分20
21秒前
善学以致用应助橙猫猫采纳,获得10
22秒前
GEZIKU完成签到 ,获得积分10
24秒前
25秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Mechanistic Modeling of Gas-Liquid Two-Phase Flow in Pipes 2500
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 720
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
Typology of Conditional Constructions 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3566811
求助须知:如何正确求助?哪些是违规求助? 3139560
关于积分的说明 9431989
捐赠科研通 2840353
什么是DOI,文献DOI怎么找? 1560990
邀请新用户注册赠送积分活动 730141
科研通“疑难数据库(出版商)”最低求助积分说明 717855